MedTrace Logo

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

NCT00428337 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-10-14

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of and immune response to two experimental vaccines, designed for use in combination, for the prevention of HIV infection in healthy adults.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

EP-1233

DNA-HIV-recombinant vaccine

BIOLOGICAL

MVA-mBN32

HIV-recombinant viral vaccine

Sponsors & Collaborators

  • HIV Vaccine Trials Network

    collaborator NETWORK

  • Pharmexa-Epimmune

    collaborator UNKNOWN

  • Bavarian Nordic

    collaborator INDUSTRY

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Geoffrey Gorse · Saint Louis University School of Medicine

  • Christine Mhorag Hay · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00428337 on ClinicalTrials.gov